check_circleStudy Completed
Diabetes Mellitus
Bayer Identifier:
13066
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Prevention of postprandial hyperglycemia by acarbose may be a promising therapeutic strategy for reducing the increased risk for cardiovascular disease
Trial purpose
The use of acarbose in impaired glucose tolerance (IGT) and type 2 diabetic subjects has been associated with a significant reduction of cardiovascular events. Additionally, acarbose has been shown to have a beneficial influence on some of the other cardiovascular risk factors (metabolic syndrome components). Thus, prevention of postprandial hyperglycemia by acarbose may be a promising therapeutic strategy for reducing the increased risk for cardiovascular disease. Further studies are needed to confirm the influence of acarbose on cardiovascular risk factors in the real life setting.
Key Participants Requirements
Sex
BothAge
18 - N/ATrial summary
Enrollment Goal
3310Trial Dates
May 2007 - June 2008Phase
N/ACould I Receive a placebo
NoProducts
Acarbose (Precose/Glucobay, BAYG5421)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Many Locations, Poland |
Primary Outcome
- Safety, tolerability of acarbose and its effect on body weight, waist circumference and blood pressuredate_rangeTime Frame:approximately 6 months after acarbose treatment initiationenhanced_encryptionNoSafety Issue:
Secondary Outcome
- Effect of acarbose on HbA1c, fasting and postprandial glycemia and on lipid profiledate_rangeTime Frame:approximately 6 months after acarbose treatment initiationenhanced_encryptionYesSafety Issue:
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A